» Articles » PMID: 36540004

Factors Affecting Performance of Insulin Pen Injector Technology: A Narrative Review

Overview
Specialty Endocrinology
Date 2022 Dec 21
PMID 36540004
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Insulin treatment is an essential hormone replacement therapy for the survival of people with type 1 diabetes and is often used for treatment in type 2 diabetes, particularly as the disease progresses. Advances in insulin therapy have been made since its discovery, including production of human insulin and development of insulin analogs with improved efficacy and safety profiles. The different types of available insulin formulations allow health care professionals to personalize treatment to an individual's needs. Generally, insulin requires parenteral administration via subcutaneous injection owing to very low oral bioavailability.

Methods: This article reviews the human, technological, economical, and regulatory factors affecting the performance of insulin pens and the relationship between them. Opportunities and challenges that insulin pen injections may encounter in the future are also considered.

Results: Insulin delivery devices, together with other factors, influence dose accuracy, convenience, and quality of life, contributing to easier medication administration with high efficacy and safety. For patients, ease of use, fast and accurate drug delivery, and painless injection are the most valuable features of an insulin injection device. For manufacturers, technological feasibility and economic viability also need to be considered when developing injection devices.

Conclusion: Insulin pen injectors are generally preferred over vial and syringe, although access may be limited in some health care systems. Insulin pen injectors can adapt to different insulin regimens and formulations and have the potential to acquire dosing data in real time.

Citing Articles

Transitioning to Insulin Analogs in Tunisian Children with Type 1 Diabetes: Efficacy and Safety.

Marzouk A, Lajili M, Ben Yahya I, Thebti R, Ayeb S, Bouaziz A Tunis Med. 2024; 102(8):452-456.

PMID: 39129571 PMC: 11390061. DOI: 10.62438/tunismed.v102i8.4435.


Preference for a Novel Oral Alternative to Parenterally Administered Medications.

Myers J, Dam J, Imran M, Hashim M, Dhalla A Patient Prefer Adherence. 2024; 18:1547-1562.

PMID: 39100431 PMC: 11298207. DOI: 10.2147/PPA.S463354.


Novel Robust Needle Tip Design Enables Needle Reuse and Reduced Skin Trauma in Combination With Autoinjector Needle Shields.

Staples A, Schwartz J, Praestmark K, Traberg M J Diabetes Sci Technol. 2023; 19(2):352-360.

PMID: 37559407 PMC: 11874290. DOI: 10.1177/19322968231190408.

References
1.
Marcus A . Diabetes care - insulin delivery in a changing world. Medscape J Med. 2008; 10(5):120. PMC: 2438492. View

2.
Hemmingsen H, Niemeyer M, Hansen M, Bucher D, Thomsen N . A prefilled insulin pen with a novel injection mechanism and a lower injection force than other prefilled insulin pens. Diabetes Technol Ther. 2011; 13(12):1207-11. DOI: 10.1089/dia.2011.0110. View

3.
Lau J, Dunn M . Therapeutic peptides: Historical perspectives, current development trends, and future directions. Bioorg Med Chem. 2017; 26(10):2700-2707. DOI: 10.1016/j.bmc.2017.06.052. View

4.
Rosselli J, Archer S, Lindley N, Butler L . U300 Insulin Glargine: A Novel Basal Insulin for Type 1 and Type 2 Diabetes. J Pharm Technol. 2021; 31(5):234-242. PMC: 5990197. DOI: 10.1177/8755122515584193. View

5.
Li-Geng T, Kilham J, McLeod K . Cultural Influences on Dietary Self-Management of Type 2 Diabetes in East Asian Americans: A Mixed-Methods Systematic Review. Health Equity. 2020; 4(1):31-42. PMC: 7081245. DOI: 10.1089/heq.2019.0087. View